META vs RDCM

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.

RDCM exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a nearly debt-free balance sheet (Debt/Equity 0.03). While the current price of $12.86 is slightly above the defensive Graham Number ($10.48), it trades at a significant discount to its growth-based intrinsic value of $20.95. The company demonstrates a powerful earnings track record with consistent beats over 25 quarters and strong YoY earnings growth of 50.90%. Despite a bearish technical trend, the fundamental valuation and profitability metrics suggest a strong undervalued growth opportunity.